474791 | InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

474791
Non è stato possibile trovare il prezzo
Minimum Quantity needs to be mulitiple of
Al termine dell'ordine Maggiori informazioni
Lei ha salvato ()
 
Richiedi il prezzo
Disponibilità limitata Disponibilità limitata
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Remaining : Will advise
      Will advise
      Visualizza prezzi e disponibilità
         ConfrontaClick To Print This Page

      Overview

      Replacement Information

      Tabella delle specifiche principali

      Empirical Formula CAS #
      C₂₆H₄₁N₃O₅ 133407-82-6

      Prezzi e disponibilità

      Numero di catalogoDisponibilità Confezionamento Qtà/conf Prezzo Quantità
      474791-1MG
      Verifica della disponibilità in corso...
      Disponibilità limitata Disponibilità limitata
      Fuori produzione
      Disponibili quantità limitate
      La disponibilità deve essere confermata
        Remaining : Will advise
          Will advise

          1 mg
          Ricerca del prezzo in corso...
          Non è stato possibile trovare il prezzo
          Minimum Quantity needs to be mulitiple of
          Al termine dell'ordine Maggiori informazioni
          Lei ha salvato ()
           
          Richiedi il prezzo
          474791-5MG
          Verifica della disponibilità in corso...
          Disponibilità limitata Disponibilità limitata
          Fuori produzione
          Disponibili quantità limitate
          La disponibilità deve essere confermata
            Remaining : Will advise
              Will advise

              5 mg
              Ricerca del prezzo in corso...
              Non è stato possibile trovare il prezzo
              Minimum Quantity needs to be mulitiple of
              Al termine dell'ordine Maggiori informazioni
              Lei ha salvato ()
               
              Richiedi il prezzo
              Description
              Catalogue Number 474791
              Brand Family Calbiochem®
              Synonyms Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              References
              References Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Product Information
              CAS number 133407-82-6
              ATP Competitive N
              Form Liquid
              Formulation A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Hill Formula C₂₆H₄₁N₃O₅
              Chemical formula C₂₆H₄₁N₃O₅
              Molar Mass 475.6
              Reversible Y
              Applications
              Biological Information
              Primary Target proteasome
              Primary Target IC50 3 µM in inhibiting NF-κB activation
              Primary Target Ki 4 nM as proteasome inhibitor
              Purity ≥98% by HPLC
              Physicochemical Information
              Cell permeable Y
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              R Phrase R: 36/38

              Irritating to eyes and skin.
              S Phrase S: 26-36-45

              In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
              Wear suitable protective clothing.
              In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Blue Ice Only
              Toxicity Irritant
              Storage -20°C
              Protect from Light Protect from light
              Do not freeze No
              Special Instructions Following initial thaw, aliquot and freeze (-20°C).
              Packaging Information
              Packaged under inert gas Packaged under inert gas
              Transport Information
              Supplemental Information
              Specifications

              Documentation

              MSDS

              Lingue
              Argentina Australia Bahasa Melayu
              Belgie Belgien Belgique
              Brasil Canadian English Canadian French
              Ceská Rep Chile China
              Colombia Cyprus Danmark
              Deutschland Eesti Ellas
              English España France
              Hrvatska  Iceland India
              Indonesia Italia Korea
              Latvija Lietuva Magyarország
              Malaysia Malta México
              Nederland  Norge Peru
              Polska Portugal Romania
              Schweiz Slovenija Slovensko
              South Africa Srpski Standard EU English
              Suisse Suomi Sverige
              Svizzera Taiwan Thailand
              Türkiye US English US Español
              United Kingdom Venezuela Vietnamese
              Éire Österreich България
              Россия

              Certificati d'Analisi

              TitoloNumero di lotto
              474791

              Riferimenti bibliografici

              Panoramica delle referenze
              Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.

              Citazioni

              Titolo
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
            • Scheda tecnica

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revision 03-June-2013 JSW
              Synonyms Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              Description Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
              Form Liquid
              Formulation A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Intert gas (Yes/No) Packaged under inert gas
              CAS number 133407-82-6
              Molar mass 475.6
              Chemical formula C₂₆H₄₁N₃O₅
              Purity ≥98% by HPLC
              Storage -20°C
              Protect from light
              Do Not Freeze No
              Special Instructions Following initial thaw, aliquot and freeze (-20°C).
              Toxicity Irritant
              References Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Citation
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.